Quick Answer
Dual GIP and GLP-1 receptor agonists are being tested in addiction because GLP-1 receptors sit in the brain's reward circuits and GLP-1 drugs reduce alcohol intake in animals. In rodents, tirzepatide reduced alcohol drinking and relapse-like behaviour, and health-record studies link it with fewer new alcohol use disorder diagnoses. The randomised human evidence is still small, and as of November 2026 no dual agonist has reported a trial in any psychiatric condition.
Key facts
- Compounds in focus: tirzepatide (approved for type 2 diabetes and weight management) and brenipatide (investigational), both dual GIP and GLP-1 receptor agonists.
- Strongest evidence type: rodent studies and observational health-record studies.
- Randomised human trials reported: GLP-1 receptor agonists only (exenatide, semaglutide, dulaglutide), all small, with mixed results.
- Registered pipeline: 34 ongoing randomised psychiatric trials of incretin drugs on ClinicalTrials.gov as of September 2026, half of them testing a co-agonist.
- Approval status (November 2026): no incretin drug is approved for any substance use or psychiatric disorder.
Reports that people taking GLP-1 drugs lost interest in alcohol have turned into one of the largest repurposing efforts in psychiatry. Most of the attention has gone to semaglutide, which acts on the GLP-1 receptor alone. The newer question is whether adding GIP receptor activity, as tirzepatide and brenipatide do, changes anything. This article sets out what each kind of evidence shows and where the gaps are.
Why look at incretin drugs for addiction?
GLP-1 is best known as a gut hormone that raises insulin release after meals and reduces appetite. Its receptors are also found in the brain, including areas of the mesolimbic reward system that respond to alcohol, nicotine and other drugs. In rodents and non-human primates, GLP-1 receptor agonists reduce alcohol intake and the release of dopamine that alcohol normally triggers (Klausen et al., 2022). That is the biological case. Our guide to GLP-1 peptides covers the receptor in more detail.
GIP, the second incretin hormone, has been studied much less in the brain. Its receptor is also expressed there, but whether GIP receptor activity reduces drug-seeking, does nothing, or works against GLP-1 in these circuits has not been settled.
What do the animal studies show for dual agonists?
- Tirzepatide in rodents (2026). A Swedish and US team reported that tirzepatide reduced the rewarding effects of alcohol in mice and rats, measured by locomotor stimulation, place preference and dopamine release in the nucleus accumbens. It also reduced voluntary drinking, prevented binge-like and relapse-like drinking, and kept working with repeated treatment (Edvardsson et al., 2026).
- Alcohol's felt effects in rats (2026). In a drug-discrimination study, semaglutide, tirzepatide and retatrutide each blunted rats' ability to recognise the internal cues of alcohol, which the authors read as a change in alcohol's subjective effects (Windram et al., 2026).
Neither study was designed to separate the GIP part from the GLP-1 part, so they show that dual agonists act on alcohol-related behaviour in rodents, not that GIP adds to it.
What do human studies show?
Randomised trials, GLP-1 receptor agonists only:
- Exenatide, 2022: in 127 people with alcohol use disorder over 26 weeks, no reduction in heavy drinking days overall, the primary outcome, but reduced brain responses to alcohol cues on imaging (Klausen et al., 2022).
- Semaglutide, 2025: in 48 adults over 9 weeks, less alcohol drunk in a laboratory session, fewer drinks per drinking day and less craving, but no change in the number of drinking days (Hendershot et al., 2025).
- Dulaglutide, 2024: added to standard smoking cessation treatment in 255 people, it did not improve abstinence at 12, 24 or 52 weeks (Lüthi et al., 2024).
A 2025 meta-analysis pooled three randomised trials (430 people) and found non-significant reductions in alcohol consumption and craving; the six observational studies it included showed fewer alcohol-related events (Sinha and Ghosal, 2025).
Observational studies, including tirzepatide:
- In US health records of 83,825 people with obesity, semaglutide was associated with a 50% to 56% lower risk of new or recurrent alcohol use disorder diagnoses over 12 months, compared with other weight medicines (Wang et al., 2024).
- In Sweden, among 227,866 people with alcohol use disorder, periods on semaglutide were associated with fewer alcohol-related hospital admissions than periods off it (Lähteenvuo et al., 2025).
- In people with type 2 diabetes, a UK team using US health records found tirzepatide associated with a lower risk of a first alcohol use disorder diagnosis than DPP-4 inhibitors (hazard ratio 0.47), and lower than liraglutide in a head-to-head comparison (Henney et al., 2026).
Observational studies can show an association but not cause. People prescribed these drugs differ from those who are not, and a diagnosis code is a crude measure of drinking.
Is there genetic evidence for GIP?
One line of evidence points at GIP directly. A 2025 drug-target Mendelian randomisation study used natural variation in the GIP and GLP-1 receptor genes as a stand-in for lifelong receptor activity. Variants modelling the effects of both receptors were linked with less binge drinking and less heavy drinking, and each gene on its own appeared protective. The same analysis found no link with tobacco, cannabis or opioid use disorders (Reitz et al., 2025). Genetic proxies are not the same as a drug, but this is the clearest hint so far that GIP may matter in its own right.
What trials are registered?
A review of ClinicalTrials.gov on 1 September 2026 found 34 ongoing randomised trials of incretin drugs with a psychiatric or addiction outcome as the primary measure, planning to enrol 8,519 people (Fagiolini and Cuomo, 2026). Three compounds accounted for all of them, and 17 tested a GLP-1-containing co-agonist. Alcohol use disorder had 14 trials, tobacco or nicotine 5, opioid use disorder 4 and major depressive disorder 3. Seven trials of one co-agonist from one sponsor made up 62% of planned enrolment; by our count those figures match brenipatide's RENEW psychiatric trials.
- Brenipatide: phase 3 trials in alcohol use disorder (RENEW-ALC-1, RENEW-ALC-2) and in relapse prevention in major depressive disorder, plus phase 2 trials in smoking relapse, opioid use disorder, bipolar disorder and depression with a partial response to antidepressants. The brenipatide profile lists every registered study.
- Tirzepatide: academic trials, including the US TAB trial of tirzepatide added to buprenorphine in about 310 adults with opioid use disorder, with six-month treatment retention as the primary outcome (Winhusen et al., 2026).
The same review found six further trials in schizophrenia-spectrum disorders whose primary outcomes are metabolic, such as body weight, rather than psychiatric. Brenipatide's schizophrenia trial is one of these.
What will the trials be able to tell us?
The review's authors make a point that matters for anyone reading future results: because half of the trials use co-agonists, a positive result would not show which receptor is responsible. A dual agonist that reduces drinking could be doing so through GLP-1 alone. Answering the GIP question would need a trial that compares a dual agonist with a GLP-1-only drug, or a GIP-only compound, in the same population. None is registered.
There is also the weight question. Many of these trials enrol people regardless of body weight, and incretin drugs reduce appetite and weight. Separating a direct effect on drinking or craving from the general effects of eating less is part of what the larger trials are designed to do.
What is not known yet?
- Whether any dual agonist works in people. No randomised trial of tirzepatide or brenipatide in a substance use or psychiatric disorder has reported.
- The role of GIP. Supported by one genetic study and untested pharmacologically in humans.
- Which substances respond. Alcohol has the most data. The genetic study found nothing for tobacco, cannabis or opioids, and dulaglutide did not help smokers stay abstinent.
- Durability. The randomised trials so far ran for 9 to 26 weeks. The phase 3 trials run for a year or more.
The bottom line
The case for testing GIP and GLP-1 dual agonists in addiction rests on rodent studies, large but observational health-record studies and one genetic analysis, on top of small and mixed randomised trials of GLP-1 drugs alone. Whether a dual agonist changes drinking, smoking or mood in people is unknown. The brenipatide RENEW trials, the first of which has a registry completion estimate in 2027, and the academic tirzepatide trials will start to answer that, but even a positive result may not say what GIP contributes. For the trial-by-trial detail, see the RENEW trials explained and our brenipatide research overview.
References
- Edvardsson CE, et al. (2026). Tirzepatide reduces alcohol drinking and relapse-like behaviours in rodents. eBioMedicine. PubMed 41506148
- Fagiolini A, Cuomo A. (2026). Incretin-based therapies in psychiatry: A landscape analysis of ongoing randomized trials registered on ClinicalTrials.gov. Journal of Psychiatric Research. PubMed 42962407
- Hendershot CS, et al. (2025). Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. PubMed 39937469
- Henney AE, et al. (2026). Relative efficacy of GLP-1 and GLP-1/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach. Diabetes, Obesity and Metabolism. PubMed 41058240
- Klausen MK, et al. (2022). The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. British Journal of Pharmacology. PubMed 34532853
- Klausen MK, et al. (2022). Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight. PubMed 36066977
- Lähteenvuo M, et al. (2025). Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder. JAMA Psychiatry. PubMed 39535805
- Lüthi H, et al. (2024). Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial. eClinicalMedicine. PubMed 38371479
- Reitz J, et al. (2025). Genetically modeled GLP1R and GIPR agonism reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target Mendelian randomization study. Molecular Psychiatry. PubMed 40931165
- Sinha B, Ghosal S. (2025). The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis. Addiction Science and Clinical Practice. PubMed 41350683
- Wang W, et al. (2024). Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications. PubMed 38806481
- Windram M, et al. (2026). Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats. Psychopharmacology. PubMed 40699363
- Winhusen TJ, et al. (2026). Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the treatment of opioid use disorder (TAB) trial: study design and rationale. Contemporary Clinical Trials. PubMed 42600923